Huadong Medicine's (SHE:000963) unit, Hangzhou Sino-US Huadong Pharmaceutical, has received a medical device registration certificate from China's drug administration for its Transcutaneous Glomerular Filtration Rate Measurement Device.
The newly approved device consists of a host unit, a sensor, and a fixing sticker, and is designed for non-invasive measurement of glomerular filtration rate (GFR). GFR is a key indicator of kidney function.
The company's shares rose more than 1% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。